Recruiting × Colorectal Neoplasms × pembrolizumab × Clear all BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Phase 1 Recruiting
387 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Phase 1/2 Recruiting
252 enrolled
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/2 Recruiting
300 enrolled
MK-3475-C66
Phase 3 Recruiting
100 enrolled
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Phase 1/2 Recruiting
295 enrolled
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Phase 2 Recruiting
332 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Phase 1 Recruiting
330 enrolled
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 Recruiting
240 enrolled
EBNK-ST-001
Phase 1/2 Recruiting
83 enrolled
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
450 enrolled
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
434 enrolled
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
216 enrolled
MK-9999-02A
Phase 1/2 Recruiting
220 enrolled
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Phase 1 Recruiting
495 enrolled
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Phase 1 Recruiting
130 enrolled
ProbeTILity
Phase 1/2 Recruiting
12 enrolled
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Phase 1/2 Recruiting
540 enrolled
INVOKE
Phase 1 Recruiting
166 enrolled
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Phase 1 Recruiting
292 enrolled
Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer
Phase 2 Recruiting
20 enrolled
ABILITY-1
Phase 1/2 Recruiting
115 enrolled
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
140 enrolled
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
523 enrolled
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Phase 1/2 Recruiting
358 enrolled
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Phase 2 Recruiting
110 enrolled
BAH248
Phase 1/2 Recruiting
85 enrolled
Development and Analysis of a Stool Bank for Cancer Patients
Recruiting
100 enrolled
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Phase 1/2 Recruiting
125 enrolled
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Phase 1 Recruiting
38 enrolled
EVIDENT
Phase 2 Recruiting
40 enrolled
ATAPEMBRO
Phase 1/2 Recruiting
47 enrolled